Promising antibody therapy may help kidney patients stay Relapse-Free longer
NCT ID NCT07233330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called obinutuzumab in 10 adults with a kidney condition called nephrotic syndrome that keeps coming back despite standard treatments. The goal is to see if a single course can keep patients relapse-free for at least 12 months by deeply depleting certain immune cells. Participants will be monitored for safety and how long the effect lasts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME，IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Ranica, BG, 24020, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.